

[Click Here For More Information About](#)

FASTest® ENCEPH

ad us. vet.

In vitro diagnosticum

Test-kit for the qualitative detection of
IgG antibodies against *Encephalitozoon cuniculi* in
whole blood, plasma or serum of the rabbit

INSTRUCTIONS FOR USE

Supplied Exclusively To The UK

Veterinary Market By

Vetlab Supplies Ltd

Visit Our Website

www.vetlabsupplies.co.uk

Telephone: 01798 874567

email us: info@vetlabsupplies.co.uk



Manufacturer:



6912 Hörbranz – AUSTRIA
www.megacor.com

1. INFORMATION ON THE TEST-KIT

TEST-KIT COMPONENTS

1 test-kit **FASTest® ENCEPH** contains:

- 2, 6 or 25 test cassettes coated with *Encephalitozoon cuniculi* antigens
- 2, 6 or 25 dropper bottles **A** with 1.0 ml buffer diluent each
- 2, 6 or 25 disposable plastic pipettes (20 µl)
- 2, 6 or 25 disposable plastic pipettes (10 µl)
- 2, 6 or 25 reaction tubes (0.5 ml)
- 1 instructions for use

STABILITY AND STORAGE



Store at
15–25°C



Expiry date
– see label

APPLICATION AND ABBREVIATIONS



For veterinary use only



Lot number



In vitro diagnosticum



Do not use test-kit components from different kits, lot numbers or beyond stated expiry date.



Follow instructions for use precisely

B – TEST line, **C** – CONTROL line, **LF** – Lateral flow

SBM – sample-buffer mixture

LIABILITY

The entire risk due to the performance of this product is assumed by the purchaser. The manufacturer shall not be liable for indirect, special or consequential damages of any kind resulting from the use of this product.

2. INTRODUCTION

The infection with *Encephalitozoon cuniculi* occurs via the extremely resistant spores by contaminated food or inhalation in contaminated surroundings. (Domestic) rabbits are primarily affected. Other strains of the pathogen cause disease in immunocompromised Old World mice and carnivores. Although very rare, it can occur in immunocompromised people (zoonosis).

Neurological symptoms, signs of kidney failure, and eye skin inflammation may occur due to lesions in the central nervous system, kidney and eye. Diseased rabbits can experience one or more of these symptoms. The most common is the so-called vestibular syndrome (head tilt, disorders of movement coordination and eye tremors). Other neurological symptoms can include seizures, incomplete paralysis, and loss of balance. In rare cases, increased aggression and loss of hearing or vision may also occur. In some animals, renal insufficiency with rather unspecific symptoms (loss of appetite or weight, dehydration, disorders of the mineral balance and bone metabolism as well as apathy) can be indicative.

The *in vivo* diagnosis of encephalitozoonosis in rabbits is problematic because of the large number of animals with chronic, asymptomatic infection. In this case, antibodies can be detected in the blood for years. The serological detection of antibodies against *E. cuniculi* is therefore considered the safest method since antibody formation begins 14–28 days after infection. A negative antibody titre after more than 14–28 days excludes an acute infection or a previous contact with *E. cuniculi* with high probability.

Therefore, the indirect detection of antibodies using **FASTest® ENCEPH** is of great diagnostic importance (exclusion diagnostics).

3. INFORMATION ON THE SPECIMEN MATERIAL

Exactly 20 µl (1 drop of attached 20 µl plastic pipette) 15–25°C warm whole blood (WB, with anticoagulant), or exactly 10 µl (1 drop of attached 10 µl plastic pipette) 15–25°C warm plasma (P) or serum (S) are needed. Native blood without anticoagulant and the anticoagulant citrate can **not** be used.

Mix the sample material well before use.

Non-cooled (15–25°C), WB, P and S should be tested within 4 hours. At 2–8°C, WB, P and S can be stored up to 4 days. Serum and/or plasma samples can be permanently stored at minimum –20°C.

Keep in mind that the sample material, as well as all used test-kit components, should have reached room temperature at the time of application.


Endogenous and exogenous interfering substances of the sample (e.g. albumin, fibrinogen, lipids, CRP, heterophilic antibodies, especially type IgA, as well as viscosity, pH-value and excess EDTA) as well as native blood can cause interferences (matrix effects) that can influence the target measurement. These can lead to an impaired LF and/or unspecific reactions on B and C.

4. SPECIMEN COLLECTION AND PREPARATION

- No specimen preparation necessary.
- If you do not have the possibility to obtain serum via centrifugation or serum separation tubes (SST), you can fill 500 µl of native blood into the enclosed reaction tube. As soon as the serum has separated from the blood cake (usually after about 15 to 30 minutes), you can continue with step 5 (Test procedure).
- TIP: The first 0.5 ml of blood contains more clotting factors. Ideally, you should use these.

5. TEST PROCEDURE

- Before opening the dropper bottle **A**, shake the entire buffer diluent down to the bottom of the bottle (fig.1).
- Remove the test cassette from its foil pouch shortly before use. Place it on a flat surface.
- a. **Whole blood:** 20 µl sample volume (fig.2a)
b. **Plasma or serum:** 10 µl sample volume (fig.2b)
- Draw sample up to the mark using the disposable plastic pipette. The meniscus must be above the black line (fig.1a/b). Place the whole sample volume into the dropper bottle **A** (hold pipette vertically, fig.3).
- Mix the sample-buffer mixture (SBM) thoroughly (fig.4).
- Break the tip of the dropper bottle **A**, hold the dropper bottle **A** vertically, discard the first drop and add 3 drops (ca. 120–150 µl) of SBM into the sample window A of the test cassette (fig.5).
- If there is no beginning pink-purple LF visible within 1 minute after adding the SBM, add 1 additional drop of SBM into the sample window A.



6. READING OF THE TEST RESULT



Read the test result **10 minutes** after the three drops of the SBM have been added into the sample window A.

POSITIVE TEST RESULT (fig.6)

A pink-purple **TEST** line of any intensity (varying from very weak to strongly intensive) and a pink-purple **CONTROL** line appear.

NEGATIVE TEST RESULT (fig.7)

Only a pink-purple **CONTROL** line appears. This line indicates, irrespective of its intensity, that the test has been performed properly.

INVALID TEST RESULT

No **CONTROL** line visible. The test should be repeated using a new test cassette.

fig.6
POSITIVE TEST RESULT





fig.7
NEGATIVE TEST RESULT



7. PRECAUTIONS FOR USERS

- The guidelines for working in medical laboratories must be observed. It is recommended to wear disposable gloves and other personal protective equipment (protective clothing, possibly a face mask). Wash and disinfect hands after completing the test.
- Label sample material, reaction tube, associated dropper bottle **A** and test cassette to ensure a precise assignment.
- Use a new reaction tube, a new dropper bottle **A**, a new pipette and a new test cassette for each sample.
- The buffer diluent contains low concentrations of toxic sodium azide as a preservative, therefore avoid skin/eye contact and/or ingestion.
- The sample material must be seen as potentially infectious and disposed of accordingly, together with the used test-kit components.

8. TEST PRINCIPLE

The **FASTest® ENCEPH** is based on an immunochromatographic “sandwich principle”.

The antibodies against *Encephalitozoon cuniculi* present in the sample will react in the conjugate pad with mobile monoclonal antibodies, which are conjugated to colloidal gold particles. These antibody complexes are migrating (“lateral flow”, **LF**) along the nitrocellulose membrane and bind to fixed recombinant *Encephalitozoon cuniculi* antigens forming a pink-purple **TEST** line (**B**).

A correct test procedure will be indicated by a second, pink-purple **CONTROL** line (**C**).

9. INFORMATION FOR THE INTERPRETATION

- The interpretation of the test result should always be based on anamnestic and clinical data as well as the therapy and prophylaxis possibilities.
- Any non-described colour or contour variation of B and C (e.g. greyish, shadow-like lines) has to be considered as unspecific reaction and therefore as negative test result.
- Due to anticoagulated whole blood and/or red hemoglobin background of the test membrane, caused by hemolytic blood samples, the visibility of B, especially in case of weak positive samples, could be from worse to not visible.
- For the detection of antibodies, a two-step diagnosis is known to be standard. The first step starts with in-clinic IgG antibody screening test like **FASTest® ENCEPH**.
> A negative **FASTest® ENCEPH** 14–28 days post infection excludes with high probability an acute infection or previous contact with *E. cuniculi*. The following diseases should be examined for differential diagnosis: otitis media/interna (rabbit cold complex), otitis externa (*Psoroptes cuniculi*), trauma, toxoplasmosis, neoplasia, herpes infection, intoxication.
- > The suspicion about an active encephalitozoonosis is substantiated by combination of **FASTest® ENCEPH** and according clinic. Furthermore, two serum samples at intervals of 2–4 weeks should be taken for quantitative antibody titre determination via indirect immunofluorescence test (**MegaFLUO® ENCEPHALITOZOON cuniculi**) or ELISA (**MegaELISA® ENCEPHALITOZOON cuniculi**) to determine the end titre or a 2- to 4-fold titre increase (seroconversion).